Martin Dreyling, MD, of the LMU University Hospital Munich, in Munich, Germany discusses new data presented at a plenary lecture presented at ASH 2022 showing ibrutinib without autologous stem cell transplantation (ASCT) is as effective as ASCT to treat patients with mantle cell lymphoma.
Mantle cell lymphoma is a rare form of non-Hodgkin’s lymphoma. For = patients with this fairly aggressive cancer, ASCT has been the standard of care (along with chemotherapy) for those who can tolerate ASCT.
At ASH 2022, Dr. Dreyling presented data from the TRIANGLE study that compared three treatment regimens in patients with advanced mantle cell lymphoma: 1) chemotherapy (3 cycles R-CHOP/R-DHAP) plus ASCT (n=288); 2) chemotherapy plus ACST plus ibrutinib (n=288); and 3) chemotherapy plus ibrutinib (n=290). The chemotherapy consisted of three cycles of R-CHOP/R-DHAP.
As Dr. Dreyling stated, the results showed patients receiving chemotherapy and ibrutinib, with or without ASCT, had results superior to ASCT. More importantly, the patients receiving ibrutinib without ASCT was just as effective as those receiving ASCT.
More specifically, the data showed that the 3-year failure-free survival (FFS) rate was 72% in the patients receiving chemotherapy, 88% in those receiving chemotherapy plus ASCT plus ibrutinib, and 86% in patients receiving chemotherapy plus ibrutinib. Further, the 3-year overall survival was 86% in the patients receiving chemotherapy, 91% in those receiving chemotherapy plus ASCT plus ibrutinib, and 92% in patients receiving chemotherapy plus ibrutinib.
Based on these results, Dr. Dreyling stated this study could be a “game changer” for treating younger patients with mantle cell lymphoma. Dr. Dreyling also noted that future studies comparing outcomes with and without chemotherapy are being planned.
To stay up-to-date on the latest data presented at ASH 2022, go to checkrare.com/diseases/hematologic-disorders/
